Patent · US Active

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

US11053296B2 · kind B2 · utility

4Cited by

9References

20Claims

0Family size

Assignee

Immatics Biotechnologies GmbH · DE

Inventors

Heiko SCHUSTER · Rötteln, DE
Janet Peper · Freising, DE
Kevin Roehle · Rötteln, DE
Philipp Wagner · Mellrichstadt, DE
Hans-Georg Rammensee · Lörrach, DE

Key dates

Filing date	Aug 20, 2020
Grant date	Jul 6, 2021
Priority date	—
Expiry date	Aug 20, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.